Practical Case Discussions: BTK inhibitor Therapy for Frontline CLL

Download these slides from our ASH 2019 live satellite symposium on frontline use of BTK inhibitors to review the most current clinical data on treating patients with CLL
John Pagel Headshot
John Pagel, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.36 MB
Released: December 6, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Related Content

Download this slideset to review the latest clinical data informing optimal management strategies for follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

Download this ExpressPoints slideset for a quick summary of the latest clinical data informing optimal management of follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Jeff P. Sharman, MD Released: October 14, 2020

In this slideset from Clinical Care Options (CCO), experts review treatment options after BTK inhibitor– and venetoclax for patients with CLL.

Jeremy S. Abramson, MD, MMSc Released: October 14, 2020

Expert insight commentary from Clinical Care Options (CCO) on use of luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) patients

Guillermo Garcia-Manero, MD Released: October 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue